Skip to content
approvedCardiovascular

Bivalirudin

Also known as: Angiomax, Angiox, BG-8967, Hirulog, Bivalirudin Trifluoroacetate

Bivalirudin (Angiomax/Angiox) is a synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor, derived from the medicinal leech protein hirudin. FDA-approved for use as an anticoagulant during percutaneous coronary intervention (PCI) and in patients with heparin-induced thrombocytopenia (HIT), bivalirudin binds directly to both the catalytic site and the anion-binding exosite of thrombin with high specificity. Unlike heparin, it does not require antithrombin as a cofactor, has a short and predictable half-life, and does not cause HIT.

4 cited references·6 researched benefits

Quick Answer

Bivalirudin (Angiomax) is an FDA-approved synthetic 20-amino acid direct thrombin inhibitor used as an anticoagulant during percutaneous coronary intervention (PCI) and cardiac procedures. Derived from leech hirudin, it binds thrombin directly with a predictable 25-minute half-life. It offers advantages over heparin including lower bleeding risk, no heparin-induced thrombocytopenia, and reliable dose-response without antithrombin dependence.

Key Facts

Mechanism
Bivalirudin is a bivalent direct thrombin inhibitor. Its N-terminal D-Phe-Pro-Arg-Pro sequence binds the thrombin active site (catalytic pocket), while a C-terminal dodecapeptide binds fibrinogen recognition exosite 1 (anion-binding exosite). This dual binding provides high affinity and specificity for thrombin. Uniquely, thrombin slowly cleaves the Arg3-Pro4 bond in bivalirudin, releasing the active site while the exosite remains occupied — this makes bivalirudin a "reversible" inhibitor with a self-limiting anticoagulant effect. Bivalirudin inhibits both free (circulating) and clot-bound thrombin, unlike heparin which primarily inhibits free thrombin. It does not bind plasma proteins, platelet factor 4, or other blood components, providing highly predictable pharmacokinetics.
Research Status
approved
Half-Life
~25 minutes
Molecular Formula
C₉₈H₁₃₈N₂₄O₃₃
Primary Use
Cardiovascular
Table of Contents

Benefits

  • Effective anticoagulation during PCI with predictable dose-response and no monitoring requirement in most casesstrong
  • Reduced major bleeding compared to heparin plus glycoprotein IIb/IIIa inhibitors (HORIZONS-AMI, EUROMAX trials)strong
  • Safe in heparin-induced thrombocytopenia (HIT) — does not cross-react with HIT antibodiesstrong
  • Short, predictable half-life (~25 min) allows rapid offset — advantageous if urgent surgery is neededstrong
  • Inhibits both free and clot-bound thrombin — superior thrombin neutralization at the clot surfacestrong
  • No natural inhibitors or reversal agent needed — effect dissipates rapidly on its ownmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous bolus + infusion (PCI — FDA-approved)0.75 mg/kg IV bolus, then 1.75 mg/kg/hr continuous infusionDuring PCI procedure, continued for up to 4 hours post-procedureACT should be checked 5 minutes after bolus. An additional 0.3 mg/kg bolus may be given if ACT <225 seconds. Post-PCI infusion at 0.2 mg/kg/hr may be continued for up to 20 hours if needed.
Intravenous infusion (HIT — off-label)0.15-0.2 mg/kg/hr continuous infusion (no bolus)Continuous until platelet recoveryLower doses used in HIT compared to PCI. Dose reduction required in renal impairment (CrCl <30 mL/min: reduce to 1 mg/kg/hr during PCI or 0.05-0.1 mg/kg/hr for HIT). Cleared partly by proteolytic cleavage and partly renally.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Bleeding (most common risk, as with all anticoagulants)common
  • Back pain during infusioncommon
  • Nauseacommon
  • Hypotensioncommon
  • Acute stent thrombosis (slightly increased early risk compared to heparin + GP IIb/IIIa inhibitors in some trials)serious
  • Major hemorrhage including retroperitoneal bleedingserious
  • Headachecommon

Frequently Asked Questions

How does bivalirudin compare to heparin during PCI?
Multiple large randomized trials have compared bivalirudin to heparin during PCI. The HORIZONS-AMI trial (3,602 STEMI patients) found bivalirudin monotherapy reduced major bleeding by 40% and all-cause mortality at 30 days compared to heparin plus GP IIb/IIIa inhibitors. However, it showed slightly higher acute stent thrombosis rates in the first 24 hours. The HEAT-PPCI trial found no bleeding benefit over heparin alone (without routine GP IIb/IIIa). Current practice generally favors bivalirudin when bleeding risk is high, in HIT patients, and when radial access is not used.
Where does bivalirudin come from (the leech connection)?
Bivalirudin is a synthetic derivative of hirudin, a 65-amino acid protein found in the saliva of the medicinal leech (Hirudo medicinalis). Leeches evolved hirudin over millions of years as a potent, specific thrombin inhibitor to keep blood flowing while feeding. Bivalirudin is a shortened, 20-amino acid synthetic analog that retains the bivalent thrombin-binding mechanism (active site + exosite 1) but with improved pharmacokinetic properties. The full-length recombinant hirudin (lepirudin) was also developed as a drug but was withdrawn due to anaphylaxis risk.
What happens if a patient on bivalirudin needs emergency surgery?
Bivalirudin's short half-life (~25 minutes) is a significant clinical advantage. Anticoagulant effect substantially dissipates within 1-2 hours of stopping the infusion in patients with normal renal function. There is no specific reversal agent, but none is typically needed. If urgent reversal is required, hemodialysis can remove bivalirudin (it is 25% dialyzable). ACT or aPTT can be checked to confirm anticoagulant offset before surgery. This predictable, rapid offset makes bivalirudin preferred over heparin in situations where emergency surgery may be needed.
Can bivalirudin be used in patients with kidney disease?
Bivalirudin is cleared approximately 80% by proteolytic cleavage and 20% renally. In patients with severe renal impairment (CrCl <30 mL/min), the half-life is extended to approximately 57 minutes, and dose reduction is required. For PCI, the infusion rate should be reduced to 1 mg/kg/hr (from 1.75 mg/kg/hr). Dialysis-dependent patients require the greatest dose reduction and close ACT monitoring. Despite requiring adjustment, bivalirudin remains an important option in renal impairment because, unlike LMWH, its clearance is only partially renal.

References

  1. 1
    Bivalirudin: a direct thrombin inhibitor for percutaneous coronary intervention(1995)PubMed ↗
  2. 2
    Bivalirudin versus heparin with or without GP IIb/IIIa inhibitors in patients with STEMI (HORIZONS-AMI)(2008)PubMed ↗
  3. 3
    Bivalirudin during primary PCI in acute myocardial infarction (EUROMAX trial)(2013)PubMed ↗
  4. 4
    Heparin monotherapy vs bivalirudin in primary PCI (HEAT-PPCI randomized trial)(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19